Seer earnings release, August 11, 2026

Seer, Inc. (SEER) · Form 8-K, Item 2.02 · Filed · SEC filing

Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

REDWOOD CITY, Calif. – August 11, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended June 30, 2026.

Recent Highlights

• Achieved revenue of $3.1 million in the second quarter of 2026

• Our collaborators from Korea University presented preliminary data at the 74 th

American Society for Mass Spectrometry Conference (ASMS), demonstrating potential of AI-driven plasma proteomics for multi-cancer screening

• Proteograph leveraged in an independent study published in

Nature Genetics, “Nanoparticle-enriched mass spectrometry proteomics in British South Asians identifies links between genetic variants, plasma protein levels and disease risk”

• Initiated enforcement of our intellectual property rights against Nanomics Biotechnology Co., Ltd., with the U.S. International Trade Commission opening an investigation into Nanomics' importation of products believed to infringe Seer’s patents

• Strong patent position exemplified by the European Patent Office concluding that Brigham and Women’s Hospital’s patent, exclusively licensed by Seer, will be maintained on the basis of claims covering particle-based enrichment for proteomics

• Repurchased approximately 200,000 Class A common shares under our share repurchase program authorization as of June 30, 2026

• Ended the quarter with approximately $209.5 million of cash, cash equivalents, and investments

"I’m proud that our technology is enabling the scientific community to do impactful work previously not possible. An important highlight this quarter was the presentation at the ASMS from our customers on how AI-driven proteomics can impact early detection of cancer,” said Omid Farokhzad, Chair and Chief Executive Officer. “During the quarter, we strengthened our commercial team, positioning Seer to better convert scientific leadership into revenue, and we took action to protect our core intellectual property on two continents."

Second Quarter 2026 Financial Results

Revenue was $3.1 million for the second quarter of 2026, a 23% decrease, compared to $4.1 million for the corresponding prior year period, primarily due to lower product and service revenue as a result of continuing macroeconomic headwinds in academic and government funding and continued elongation of sales cycles in some commercial accounts related to extended customer evaluations. Product revenue for the second quarter of 2026 was $2.3 million, consisting of sales of Proteograph instruments and consumable kits. Service revenue was $0.7 million for the second quarter of 2026. Other revenue was $0.1 million for the second quarter of 2026.

Gross profit was $1.5 million and gross margin was 49% for the second quarter of 2026.

Operating expenses were $18.3 million for the second quarter of 2026, including $1.5 million in stock-based compensation, a 19% decrease, compared to $22.6 million for the corresponding prior year period, including $3.7 million in stock-based compensation. The decrease in operating expenses was primarily driven by a decrease in employee compensation expenses, including stock-based compensation.

Net loss was $16.9 million for the second quarter of 2026, compared to $19.4 million for the corresponding prior year period.

Free cash flow, defined as net cash used in operating activities of approximately $25.0 million, less net purchases of property and equipment of approximately $265 thousand, for the six months ended June 30, 2026 was approximately negative $25.3 million.

Cash, cash equivalents and investments were approximately $209.5 million as of June 30, 2026.

2026 Guidance

Seer continues to expect full year 2026 revenue to be in the range of $16 million to $18 million, representing growth of 3% at the midpoint over full year 2025.

Webcast Information

Seer will host a conference call to discuss the second quarter 2026 financial results on Tuesday, August 11, 2026, at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at https://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.

About Seer, Inc.

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

For more information, please email us at pr@seer.bio.

Forward Looking Statements... (truncated)takes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:

Patrick Schmidt pr@seer.bio

Investor Contact:

Marissa Bych investor@seer.bio

SEER, INC.

Condensed Consolidated Statements of O perations and Comprehensive Loss

(Unaudited)

(in thousands, except share and per share amounts)

SEER, INC.

Condensed Consolidated

Balance Sheets

(Unaudited)

(in thousands, except share and per share amounts)

Financial statements

Income Statement

Three Months Ended June 30, — (in thousands, except share and per share amounts)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue:Product2,3232,7264,4335,616
Revenue:Service6797971,2192,000
Revenue:Related party40956461
Revenue:Other100119187179
Revenue:Total revenue3,1024,0515,8958,256
Cost of revenue:Product1,0111,1672,4062,541
Cost of revenue:Service347395517926
Cost of revenue:Related party696139
Cost of revenue:Other238309478478
Cost of revenue:Total cost of revenue1,5961,9403,4074,084
Cost of revenue:Gross profit1,5062,1112,4884,172
Operating expenses:Research and development8,20911,98517,01523,335
Operating expenses:Selling, general and administrative10,13810,65619,57022,098
Operating expenses:Total operating expenses18,34722,64136,58545,433
Operating expenses:Loss from operations-16,841-20,530-34,097-41,261
Other income (expense):Interest income2,0522,9924,2776,209
Other income (expense):Loss on equity method investment-2,088-1,841-3,816-3,416
Other income (expense):Other income (expense)-133-81-755
Other income (expense):Total other income (expense)-491,1543802,038
Other income (expense):Loss before provision for income taxes-16,890-19,376-33,717-39,223
Other income (expense):Provision for income taxes94819149
Other income (expense):Net loss-16,899-19,424-33,736-39,372
Other comprehensive loss:Unrealized gain (loss) on available-for-sale securities-2722-795171
Other comprehensive loss:Comprehensive loss-17,171-19,422-34,531-39,201
Other comprehensive loss:Net loss per share attributable to Class A and Class B common stockholders, basic and diluted-0.31-0.33-0.61-0.67
Other comprehensive loss:Weighted-average shares used in computing net loss per share attributable to Class A and Class B common stockholders, basic and diluted55,164,08058,087,56555,577,70958,744,490

Balance Sheet

June 30, 2026 — (in thousands, except share and per share amounts)

June 30, 2026December 31, 2025
Current assets:Cash and cash equivalents26,07547,285
Current assets:Short-term investments126,778138,612
Current assets:Accounts receivable, net2,1364,282
Current assets:Related party receivables56300
Current assets:Other receivables1,2401,370
Current assets:Inventory7,6637,795
Current assets:Prepaid expenses and other current assets2,1501,890
Current assets:Total current assets166,098201,534
Current assets:Long-term investments56,63154,686
Current assets:Operating lease right-of-use assets19,28120,488
Current assets:Property and equipment, net12,17714,754
Current assets:Restricted cash524524
Current assets:Other assets1,9274,097
Current assets:Total assets256,638296,083
Current liabilities:Accounts payable3,1615,611
Current liabilities:Accrued expenses4,9987,135
Current liabilities:Deferred revenue372341
Current liabilities:Operating lease liabilities, current2,7142,575
Current liabilities:Other current liabilities2229
Current liabilities:Total current liabilities11,26715,691
Current liabilities:Operating lease liabilities, net of current portion19,67621,077
Current liabilities:Other noncurrent liabilities158
Current liabilities:Total liabilities30,95836,776
Stockholders’ equity:Class A common stock, $0.00001 par value; 94,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 55,300,389 and 56,219,599 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively11
Stockholders’ equity:Additional paid-in capital725,723724,819
Stockholders’ equity:Accumulated other comprehensive gain (loss)-336459
Stockholders’ equity:Accumulated deficit-499,708-465,972
Stockholders’ equity:Total stockholders’ equity225,680259,307
Stockholders’ equity:Total liabilities and stockholders’ equity256,638296,083

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Seer earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.